earnings
confidence high
sentiment negative
materiality 0.75
USANA Q3 net sales $200M (-6% YoY); cuts FY2024 EPS guidance to $2.45
USANA HEALTH SCIENCES INC
2024-Q3 EPS reported
$1.96
revenue$640,890,000
- Q3 diluted EPS $0.56 vs $0.59 YoY; net sales down 6% to $200M.
- Active customers fell 3% YoY to 452,000; Greater China customers rose 6% but sales -4%.
- FY2024 outlook narrowed: net sales ~$850M (from $850-880M), EPS $2.45 (from $2.40-2.55).
- Balance sheet: $365M cash, debt-free; no shares repurchased in Q3.
- Regional weakness: North Asia -15%, Americas & Europe -7% YoY.